Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the signing of an exclusive worldwide license agreement with Sanofi (Nasdaq: SNY) for Maze’s glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe...
